A Patent Review on SARS Coronavirus Main Protease (3CLpro) Inhibitors

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is an unprecedented global health emergency causing more than 4.2 million fatalities as of 30 July 2021. Only three antiviral therapies have been approved or granted emergency use authorization by the FDA. The SARS-CoV-2 3CL protease (3CL(pro)) is deemed an attractive drug target as it plays an essential role in viral polyprotein processing and pathogenesis, although no inhibitors have been approved. This patent review discusses SARS coronavirus 3CL(pro) inhibitors that have been filed up to 30 July 2021, giving an overview on the types of inhibitors that have generated commercial interest, especially amongst drug companies. Insights into the common structural motifs required for active site binding is also discussed.

Automated summary

The pandemic caused by SARS-CoV-2 has led to a global health emergency, with only three antiviral therapies approved by the FDA so far. Inhibitors targeting the SARS-CoV-2 3CL protease have generated commercial interest, with drug companies showing particular attention to these types of inhibitors. Insights into the structural motifs required for active site binding have also been discussed.